dipyridamole has been researched along with Peripheral Arterial Disease in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Peripheral Arterial Disease: Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease." | 4.87 | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simard, T | 1 |
| Motazedian, P | 1 |
| Dhaliwal, S | 1 |
| Di Santo, P | 1 |
| Jung, RG | 1 |
| Ramirez, FD | 1 |
| Labinaz, A | 1 |
| Short, S | 1 |
| Parlow, S | 1 |
| Joseph, J | 1 |
| Rasheed, A | 1 |
| Rockley, M | 1 |
| Marbach, J | 1 |
| Domecq, MC | 1 |
| Russo, JJ | 1 |
| Chong, AY | 1 |
| Beanlands, RS | 1 |
| Hibbert, B | 1 |
| Davidson, BP | 1 |
| Belcik, JT | 1 |
| Landry, G | 1 |
| Linden, J | 1 |
| Lindner, JR | 1 |
| Azarbal, A | 1 |
| Clavijo, L | 1 |
| Gaglia, MA | 1 |
| Greenhalgh, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Martin Saborido, C | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Dundar, Y | 1 |
| Dickson, R | 1 |
| Proudlove, C | 1 |
| Fisher, M | 1 |
3 reviews available for dipyridamole and Peripheral Arterial Disease
| Article | Year |
|---|---|
Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Dipyridamole; Endovascular Procedures; Humans | 2021 |
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?
Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Periphera | 2015 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac | 2011 |
1 other study available for dipyridamole and Peripheral Arterial Disease
| Article | Year |
|---|---|
Exercise versus vasodilator stress limb perfusion imaging for the assessment of peripheral artery disease.
Topics: Aged; Ankle Brachial Index; Blood Flow Velocity; Contrast Media; Dipyridamole; Exercise Test; Extrem | 2017 |